Kenvue Inc. (NYSE:KVUE) Receives Average Recommendation of “Hold” from Brokerages

Kenvue Inc. (NYSE:KVUE) has been assigned a consensus recommendation of “Hold” from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $23.00.

A number of research firms have recently commented on KVUE. Canaccord Genuity Group lowered their target price on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. UBS Group reduced their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Citigroup lowered their price target on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. Finally, Barclays cut their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th.

Kenvue Stock Up 1.2 %

Shares of NYSE KVUE opened at $22.26 on Thursday. The firm has a fifty day simple moving average of $21.28 and a two-hundred day simple moving average of $22.14. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $42.68 billion, a PE ratio of 42.00, a price-to-earnings-growth ratio of 2.57 and a beta of 1.45.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts expect that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.68%. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Institutional Trading of Kenvue

A number of institutional investors and hedge funds have recently modified their holdings of KVUE. Neo Ivy Capital Management purchased a new stake in shares of Kenvue during the fourth quarter valued at $8,229,000. Vise Technologies Inc. bought a new position in Kenvue during the 4th quarter valued at about $242,000. Financial Avengers Inc. boosted its holdings in shares of Kenvue by 44.0% during the 4th quarter. Financial Avengers Inc. now owns 66,984 shares of the company’s stock valued at $1,430,000 after acquiring an additional 20,454 shares during the last quarter. Royal Capital Wealth Management LLC grew its stake in shares of Kenvue by 5.0% in the fourth quarter. Royal Capital Wealth Management LLC now owns 28,811 shares of the company’s stock worth $615,000 after acquiring an additional 1,384 shares during the period. Finally, Kinloch Capital LLC raised its holdings in shares of Kenvue by 5.5% during the fourth quarter. Kinloch Capital LLC now owns 85,263 shares of the company’s stock valued at $1,820,000 after purchasing an additional 4,470 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.